amifostine anhydrous has been researched along with Abdominal Neoplasms in 1 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Abdominal Neoplasms: New abnormal growth of tissue in the ABDOMEN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koukourakis, MI | 1 |
| Kyrias, G | 1 |
| Kakolyris, S | 1 |
| Kouroussis, C | 1 |
| Frangiadaki, C | 1 |
| Giatromanolaki, A | 1 |
| Retalis, G | 1 |
| Georgoulias, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer[NCT00137358] | Phase 1 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to unable to obtain funding to conduct study) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for amifostine anhydrous and Abdominal Neoplasms
| Article | Year |
|---|---|
Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
Topics: Abdominal Neoplasms; Adult; Aged; Amifostine; Chi-Square Distribution; Dose Fractionation, Radiation | 2000 |